Scientific ReportsNeurosciencePeer-reviewed journal article
Modulating the Unfolded Protein Response with ISRIB Mitigates Cisplatin Ototoxicity
Jiang LiiD, Stephanie L. RouseiD, Ian R. Matthews, Yesai ParkiD, Yasmin EltawiliD, Elliott H. SherriD, Dylan K. ChaniD
Abstract
Cisplatin is a commonly used chemotherapy agent with a nearly universal side effect of sensorineural hearing loss. The cellular mechanisms underlying cisplatin ototoxicity are poorly understood. Efforts in drug development to prevent or reverse cisplatin ototoxicity have largely focused on pathways of oxidative stress and apoptosis. An effective treatment for cisplatin ototoxicity, sodium thiosulfate (STS), while beneficial when used in standard risk hepatoblastoma, is associated with reduced survival in disseminated pediatric malignancies, highlighting the need for more specific drugs without potential tumor protective effects. The unfolded protein response (UPR) and endoplasmic reticulum (ER) stress pathways have been shown to be involved in the pathogenesis of noise-induced hearing loss and cochlear synaptopathy in vivo, and these pathways have been implicated broadly in cisplatin cytotoxicity. This study sought to determine whether the UPR can be targeted to prevent cisplatin ototoxicity. Neonatal cochlear cultures and HEK cells were exposed to cisplatin and UPR-modulating drugs, and UPR marker gene expression and cell death measured. Treatment with ISRIB, a drug that activates eif2B and downregulates the pro-apoptotic PERK/CHOP pathway of the UPR, was tested in an in vivo mouse model of cisplatin ototoxicity and well as a head and neck squamous cell carcinoma (HNSCC) cell-based assay of cisplatin cytotoxicity. Cisplatin exhibited a biphasic, non-linear dose-response of cell death and apoptosis that correlated with different patterns of UPR marker gene expression in HEK cells and cochlear cultures. ISRIB treatment protected against cisplatin-induced hearing loss and hair-cell death, but did not impact cisplatins cytotoxic effects on HNSCC cell viability, unlike STS. These findings demonstrate that targeting the pro-apoptotic PERK/CHOP pathway with ISRIB can mitigate cisplatin ototoxicity without reducing anti-cancer cell effects, suggesting that this may be a viable strategy for drug development.
- organism: mouse
- research focus: drug response / drug discovery
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell-cell communication
- approach: experimental assay
- Citations
- 7
- FWCI
- 1.95
- Field percentile
- top 15%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Otoprotective effect of MnTBAP in cisplatin-induced hearing loss
Shomaila Mehmood, Pankaj Bhatia, Samson Jamesdaniel·PLoS ONEPeer-reviewed·Sep 21, 2026
- Necroptosis and apoptosis contribute to cisplatin and aminoglycoside ototoxicity
Douglas S. Ruhl, Tingting Du, … Jung‐Bum Shin·Journal of NeurosciencePeer-reviewed·Feb 7, 2019
- In silico transcriptomics identifies FDA-approved drugs and biological pathways for protection against cisplatin-induced hearing loss
Pezhman Salehi, Marisa Zallocchi, … Jian Zuo·bioRxiv·Jan 26, 2022
- Effects of Cholesterol Modulation on Cisplatin-Induced Hearing Loss
John Lee, Marcello Peppi, … Lisa L. Cunningham·bioRxiv·Sep 23, 2025
- Integrated Stress Response Inhibition Provides Sex-Dependent Protection Against Noise-Induced Cochlear Synaptopathy
Stephanie L. Rouse, Ian R. Matthews, … Dylan K. Chan·Scientific ReportsPeer-reviewed·Oct 22, 2020
- Matrix metalloproteinases proteolyze RAB proteins and contribute to cisplatin-induced ototoxicity
Zahra Zandi, Bridgette Hartley, … Amit P. Bhavsar·bioRxiv·Mar 3, 2026